Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology

Molecular Neurodegeneration

Todd E Golde²  Barbara A Osborne³  Abdul Fauq¹  Ghulam Maharvi¹  Thomas Kukar⁴  Kevin Felsenstein²  Paramita Chakrabarty²  Lisa Minter³  Christophe Verbeeck¹  Pritam Das¹ 

[1] Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA;Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL, 32608, USA;Department of Veterinary & Animal Sciences, University of Massachusetts, 661 N. Pleasant St., Amherst, MA, 01003, USA;Department of Pharmacology and Neurology, Emory University School of Medicine, 1510 Clifton Rd NE, 5123 Rollins Research Center, Atlanta, GA, 30322, USA

关键词: γ-secretase inhibition;    Therapeutics;    APP;    Alzheimer’s disease;    Aβ;   

Others  :  863782
DOI  :  10.1186/1750-1326-7-39

 received in 2012-06-22, accepted in 2012-08-06,  发布年份 2012

【 摘 要 】

Background

Alzheimer’s disease (AD) is the leading cause of dementia among the elderly. Disease modifying therapies targeting Aβ that are in development have been proposed to be more effective if treatment was initiated prior to significant accumulation of Aβ in the brain, but optimal timing of treatment initiation has not been clearly established in the clinic. We compared the efficacy of transient pharmacologic reduction of brain Aβ with a γ-secretase inhibitor (GSI ) for 1–3 months (M) treatment windows in APP Tg2576 mice and subsequent aging of the mice to either 15M or 18M.

Results

These data show that reducing Aβ production in a 2-3M windows both initiated and discontinued before detectable Aβ deposition has the most significant impact on Aβ loads up to 11M after treatment discontinuation. In contrast, initiation of treatment for 3M windows from 7-10M or 12-15M shows progressively decreasing efficacy.

Conclusions

These data have major implications for clinical testing of therapeutics aimed at lowering Aβ production, indicating that; i) these therapies may have little efficacy unless tested as prophylactics or in the earliest preclinical stage of AD where there is no or minimal Aβ accumulation and ii) lowering Aβ production transiently during a critical pre-deposition window potentially provides long-lasting efficacy after discontinuation of the treatment.

【 授权许可】

   
2012 Das et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jack CR Jr, et al.: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9(1):119-128.
• [2]Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
• [3]Dubois B, et al.: Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9(11):1118-1127.
• [4]Golde TE, Petrucelli L, Lewis J: Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol 2010, 223(2):252-266.
• [5]Imbimbo BP, Giardina GA: gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem 2011, 11(12):1555-1570.
• [6]Golde TE, Schneider LS, Koo EH: Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011, 69(2):203-213.
• [7]Das P, et al.: Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001, 22(5):721-727.
• [8]Abramowski D, et al.: Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 2008, 327(2):411-424.
• [9]Levites Y, et al.: Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 2006, 116(1):193-201.
• [10]Jarrett JT, Lansbury PT Jr: Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993, 73(6):1055-1058.
• [11]Kawarabayashi T, et al.: Age-Dependent Changes in Brain, CSF, and Plasma Amyloid Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease. J Neurosci 2001, 21:372-381.
• [12]Dovey H, Varghese J, Anderson JP: Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in the brain. J Neurochem 2000, 76:1-10.
• [13]Wong GT, et al.: Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004, 279(13):12876-12882.
• [14]Karlnoski RA, et al.: Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J Neurosci 2009, 29(15):4964-4971.
• [15]Fauq AH, et al.: A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers. Bioorg Med Chem Lett 2007, 17(22):6392-6395.
• [16]Chakrabarty P, et al.: Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 2010, 24(2):548-559.
• [17]Chakrabarty P, et al.: IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 2010, 184(9):5333-5343.